Sinovac's COVID-19 vaccine
Risk of Bell's Palsy, a type of facial paralysis, is higher after the first dose of Sinovac Biotech Ltd's (SVA.O) COVID-19 vaccine CoronaVac, according to a study published in The Lancet Infectious Diseases journal.
"The beneficial and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of this generally self-limiting adverse event," the study mentioned.
The study conducted in more than 451,000 individuals showed 28 clinically confirmed cases of Bell's Palsy following CoronaVac, compared to 16 cases following Pfizer/BioNtech's vaccine.
"Our findings suggest an overall increased risk of Bell's palsy after CoronaVac vaccination," according to the study.
The study performed in Hong Kong assessed the risk of the adverse event within 42 days following vaccination.
Sinovac did not immediately respond to a request for a comment.
Reporting by Aishwarya Nair in Bengaluru; Editing by Rashmi Aich
Afghan Women Speaks on Unyielding Hope of Restoring Their Homeland
QF to Host Education-Focused Virtual Events at United Nations General Assembly and Global Goals Week
This Manpower Firm in Doha Guides You in Hiring Nurse for Your Hospital
Qatar SC wins HH the Amir’s Table Tennis Cup 2020-2021 season
Pfizer: Know all about the Covid-19 vaccine and its usage in Qatar
FIFA’22 over Covid-19: Qatar limbers up for the World Cup amidst a worldwide pandemic
Top 5 Art Galleries You Must Explore in Qatar
The Expert Outsourcing Service in Qatar That Guides You in Employing a Qualified Graphic Designer